ClinicalTrials.gg
RecruitingNCT07634549Updated Jun 9, 2026

Rice-derived Recombinant Human Serum Albumin for the Treatment of Hypoalbuminemia After Hepatectomy: A Prospective, Single-Arm, Exploratory Clinical Trial

A Phase 4 interventional study of Rice-derived recombinant human serum albumin (OsrHSA) in Post-hepatectomy Hypoalbuminemia, sponsored by Cheng Qi. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Cheng Qi · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Rice-derived recombinant human serum albumin (OsrHSA) possesses an identical primary, secondary, and higher-order structure to plasma-derived human albumin. Through innovative production technology, it fundamentally circumvents the supply limitations and viral contamination risks associated with plasma sources, offering a novel solution to address clinical unmet needs. Existing research data have demonstrated that its efficacy and safety are non-inferior to plasma-derived human albumin in patients with cirrhosis complicated by hypoalbuminemia. However, no study has yet explored the safety and efficacy of OsrHSA in patients with postoperative hypoalbuminemia following hepatectomy. This study is a prospective, single-arm, small-sample, exploratory clinical trial aimed at evaluating the efficacy and safety of recombinant human serum albumin injection (rice) (OsrHSA) in patients with hypoalbuminemia after hepatectomy. All trial participants will receive daily intravenous infusion of 20 g OsrHSA (20%, 50 mL) starting from the day when postoperative hypoalbuminemia (\<30 g/L) is identified, with concurrent monitoring of serum albumin levels. The primary endpoints are the percentage of trial participants achieving serum albumin ≥35 g/L within one week, and the incidence of adverse drug reactions.

02

Conditions studied

  • Post-hepatectomy Hypoalbuminemia

Browse trials for

03

In context

Hypoalbuminemia

41 studies on the registry are indexed under Hypoalbuminemia; 9 are open to participants now.

This study's planned enrollment of 50 is below the median of 70 across 25 interventional studies indexed under Hypoalbuminemia.

Browse Hypoalbuminemia studies →

Lead sponsor

This is the only study on the registry with Cheng Qi as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and willing to sign the form.
  • Male or female; age ≥18 years and ≤80 years.
  • Planned for or has undergone hepatectomy.
  • Developed postoperative hypoalbuminemia, defined as serum albumin ≤30 g/L .

Exclusion criteria

Exclusion Criteria:

  • Known to the active ingredient or any of the drug
  • Complicated with any of the following diseases or conditions: severe renal disease requiring hemodialysis, active upper gastrointestinal bleeding, hepatic encephalopathy Grade III or IV.
  • Pregnant or lactating women.
  • positive.
  • Heart failure classified as Stage C or D according to ACCF/AHA criteria.
  • History of organ transplantation.
  • Mental status that prevents the participant from understanding the nature, scope, and consequences of the study.
  • Any clinical condition that the investigator considers makes the trial participant unsuitable for participation in the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Patients receive daily intravenous infusion of 20 g rice-derived recombinant human serum albumin (OsrHSA, 20%, 50 mL) starting from the day when postoperative hypoalbuminemia (\<30 g/L) is identified.

    Drug: Rice-derived recombinant human serum albumin (OsrHSA)

Interventions

  • DrugHuman serum albumin, recombinant rice-derivedStudies of Human serum albumin, recombinant rice-derivedHuman serum albumin, recombinant rice-derived pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All trial participants will receive daily intravenous infusion of 20 g Rice-derived recombinant human serum albumin (OsrHSA, 20%, 50 mL) starting from the day when postoperative hypoalbuminemia is identified, for a maximum duration of 7 days, with concurrent monitoring of serum albumin levels. Study drug administration will be discontinued once serum albumin reaches ≥35 g/L, and participants will enter the follow-up period. Each trial participant will undergo one follow-up visit within 30 days after treatment.

06

What researchers measure

Primary outcomes

  1. The percentage of trial participants achieving serum albumin ≥35 g/L within one week

    Time frame: one week after administrating rice-derived recombinant human serum albumin

Secondary outcomes

  1. Time to serum albumin ≥35 g/L (days)

    Time frame: one week after administrating rice-derived recombinant human serum albumin

  2. adverse event

    Time frame: 30 days after administrating rice-derived recombinant human serum albumin

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jul 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 9, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jul 7, 2027
CompletionEst.
Jul 31, 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07634549
Lead sponsor
Cheng Qi
Responsible party
Cheng Qi (Deputy Director of Hepatobiliary and Pancreatic Surgery Department III, Tongji Hospital) — Sponsor-investigator
First posted
Jun 9, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jul 7, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

Qi Cheng, M.D.
Contact
chengqi@hust.edu.cn
13871459541

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human serum albumin, recombinant rice-derived

Start the discussion